Detection of pancreatitis-associated protein for screening for cystic fibrosis
US5834214A · kind A · utility
5Cited by
3References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 1995 |
| Grant date | Nov 10, 1998 |
| Priority date | — |
| Expiry date | Aug 30, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/811
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to in vitro detection of human pancreatitis-associated protein (hPAP) for the purpose of screening for cystic fibrosis. hPAP is quantitated in a biological sample, preferably blood, and a high value is indicative of pancreatic dysfunction. Immunoassays as rapid, reliable methods for hPAP quantitation are provided as are antibodies for use in the assays and hybridomas for production of monoclonal antibodies preferred for use in the assays.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.